The Technical Analyst
Sierra Oncology Inc [SRRA]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Sierra Oncology Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.00% $54.99
Last updated: 7 aug 2022 - 23:25
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 342.82 mill |
| EPS: | -6.59 |
| P/E: | 0.000 |
| Earnings Date: | Aug 03, 2022 |
| SharesOutstanding: | 24.42 mill |
| Avg Daily Volume: | 0.651 mill |
| RATING 2022-07-01 |
|---|
| B+ |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$62.89 (14.37%) $7.90 |
| Date: 2022-08-08 |
| Expected Trading Range (DAY) |
|---|
|
$ 54.81 - 55.17 ( +/- 0.33%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-07-01 | Vivo Opportunity, Llc | Sell | 75 749 | Series A Warrants |
| 2022-07-01 | Vivo Opportunity, Llc | Sell | 75 749 | Series A Warrants |
| 2022-07-01 | Orbimed Advisors Llc | Sell | 170 437 | Series A Warrants |
| 2022-07-01 | Orbimed Advisors Llc | Sell | 170 437 | Series A Warrants |
| 2022-07-01 | Ashiya Mona | Sell | 170 437 | Series A Warrants |
| INSIDER POWER |
|---|
| -39.99 |
| Last 100 transactions |
| Buy: 5 559 417 | Sell: 11 118 209 |
Forecast:
16:00 - $55.00
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $55.00
Forecast 2: 16:00 - $55.00
Forecast 3: 16:00 - $55.00
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $54.99 (0.00% ) |
| Volume | 0.000 mill |
| Avg. Vol. | 0.651 mill |
| % of Avg. Vol | 0.000 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SRRA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since 31-12-69
| Date | Signal | @ | Closed | % | Jul 25 - 09:43 | buy | $54.99 | N/A | Active |
|---|
SRRA
Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company’s lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis. The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).
Latest Press Releases
2022-06-17 07:00:00 - Press Release
Sierra Oncology Announces Submission Of New Drug Application For Momelotinib To Us Food & Drug Administration
San mateo, calif.--(business wire)--sierra oncology, inc. (nasdaq: srra), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submitted a new drug application (nda) to the us food and drug administration (fda) for momelotinib, an acvr1 / alk2, jak1 and jak2 inhibitor in development for the treatment of myelofibrosis. “today is truly momentous for everyone at sierra oncology and the patients we serve. this team
2022-05-26 17:00:00 - Press Release
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation At American Society Of Clinical Oncology Annual Meeting
San mateo, calif.--(business wire)---- $srra #asco22--sierra oncology, inc. (nasdaq: srra), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the annual meeting of the american society of clinical oncology (asco) being held june 3-7, 2022, in chicago and online. an abstract presenting the full data from the pivotal phase 3 momentum study in myelofibrosis patients who are symptomatic and a
2022-05-12 10:00:00 - Press Release
Sierra Oncology Announces Oral Presentation Of Momelotinib Pivotal Phase 3 Data At European Hematology Association Annual Meeting
San mateo, calif.--(business wire)--sierra oncology, inc. (nasdaq: srra), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the 2022 annual meeting of the european hematology association (eha). an abstract presenting the full data from the pivotal phase 3 momentum study in myelofibrosis patients who are symptomatic and anemic has been selected for oral presentation. addi
2022-05-06 07:00:00 - Press Release
Sierra Oncology Reports First Quarter 2022 Results
San mateo, calif--(business wire)--sierra oncology, inc. (nasdaq: srra), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the first quarter ended march 31, 2022. “by entering into a merger agreement with gsk, we are one step closer to realizing our mission of delivering transformative therapies for patients with rare cancers, while also delivering compelling and certain val
2022-05-05 14:59:00 - Press Release
Sierra Oncology Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Sierra Oncology, Inc - Srra
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of sierra oncology, inc (nasdaqgm: srra) to glaxosmithkline plc (nyse: gsk). under the terms of the proposed transaction, shareholders of sierra will receive only $55.00 in cash for each share of sierra that they own. ksf is seeking to determine whether this consideration and the process that led to it are adequa
Latest News
2022-06-02 10:33:08 - Zacks Investment Research
GSK Receives Regulatory Nod for Consumer Healthcare Demerger
GSK progresses with the separation of its Consumer Healthcare business from biopharmaceuticals into a separate public company, Haleon, as it gets regulatory approval from the FCA.
2022-04-14 13:50:44 - Stockmarketcom
Best Biotech Stocks To Buy Now? 5 To Know
2022-04-13 13:49:54 - Invezz
Late-Stage Biopharmaceutical Sierra Oncology announces acquisition by GSK
Sierra Oncology (NASDAQ: SRRA) shares traded significantly higher after announcing the acquisition by GlaxoSmithKline PLC (LON: GSK) for $55 a share in cash. That represents a total equity value of $1.9 billion, attributed mainly to SRRA's Momelotinib, a differentiated mode of action with inhibitory activity and critical signalling pathways.
2022-04-13 11:42:38 - InvestorPlace
Why Is Sierra Oncology (SRRA) Stock Up Today?
Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring.
2022-04-13 11:20:09 - Benzinga
Sierra Oncology Stock Is Soaring: Here's Why
Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in cash, representing an approximate total equity value of $1.9 billion. GSK believes Sierra.
2022-04-13 10:10:28 - Schaeffers Research
Sierra Oncology Stock Soars After Buyout
Sierra Oncology Inc (NASDAQ:SRRA) stock is soaring today, up 38% at $54.52, after news that GlaxoSmithKline (GSK) is purchasing the company for $1.9 billion.
2022-04-13 08:32:24 - Market Watch
GSK to buy Sierra Oncology for $1.9 billion
Shares of Sierra Oncology Inc. SRRA, +3.10% soared 37.3% in premarket trading on Wednesday after GlaxoSmithKline GSK, +0.11% GSK, +0.63% said it would buy the company for $1.9 billion. Sierra is developing treatments for rare types of cancer, including myelofibrosis, and announced in January that momelotinib met the primary and secondary endpoints in a Phase 3 clinical trial evaluating the experimental therapy as a treatment for myelofibrosis.
2022-04-13 08:19:00 - Barrons
Sierra Oncology Soars After Takeover by Glaxo
The deal comes ahead of GlaxoSmithKline's planned spinoff of its consumer health division in July.
2022-04-13 08:14:41 - The Motley Fool
Why Sierra Oncology Stock Is Soaring Today
GlaxoSmithKline is adding another cancer asset to its portfolio by acquiring U.S.-based Sierra Oncology.
2022-04-13 08:08:02 - Benzinga
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal
GlaxoSmithKline plc (NYSE: GSK) has agreed to acquire Sierra Oncology Inc (NASDAQ: SRRA) for $55 per share in cash, representing an approximate total equity value of $1.9 billion (£1.5 billion). Sierra's momelotinib complements GSK's Blenrep (belantamab.